PET brain scans showing that 18 healthy volunteers (right) have on average higher levels (shown by yellow-red) of synapse marker protein SV2A than 18 participants with schizophrenia (left).

Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. The total value of the deal could rise ...

Brivaracetam is an orphan drug for the treatment of symptomatic myoclonus. It is a novel high-affinity SV2A ligand that also displays inhibitory activity at neuronal voltage-dependent sodium channels.